SCHEMBL6574096

SCHEMBL6574096

CC(C)S(=O)(=O)NCCc1ccc2cc(OCCN)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 3/20 0.47
CA12 O43570 3/20 0.40
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
CA9 Q16790 3/20 0.40
CA5A P35218 2/20 0.40
CA14 Q9ULX7 2/20 0.40
PTGS2 P35354 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
CA4 P22748 1/20 0.37
ALDH1A1 P00352 1/20 0.36
PPARG P37231 1/20 0.36
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36
CARM1 Q86X55 1/20 0.36
SLC2A1 P11166 1/20 0.36
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
ADRB3 P13945 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6765787 0.89 GRIA4 (0.46) GRIA4CA12CA1CA2CA9
SCHEMBL6763745 0.87 GRIA4 (0.48) GRIA4CA12CA1CA2CA9
SCHEMBL6571967 0.86 PTGS2 (0.45) CA12CA1CA2CA9CA5A
SCHEMBL6763716 0.86 KDM4E (0.46) GRIA4PTGS2ALDH1A1
SCHEMBL6563315 0.84 GRIA4 (0.62) GRIA4CA12CA1CA2CA9
SCHEMBL6575364 0.83 PTGS2 (0.57) GRIA4CA12CA1CA2CA9
SCHEMBL6573022 0.83 GRIA4 (0.47) GRIA4CA12CA1CA2CA9
SCHEMBL6574100 0.83 HSD17B10 (0.44) CA12CA1CA2CA9CA5A
SCHEMBL6765790 0.82 PPARG (0.59) PPARG
SCHEMBL6762744 0.80 GRIA4 (0.40) GRIA4CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147612-A1 Sulfonamide derivatives DAVISON JOSHUA ZWICK (US) 2004-07-29 US disclosed
EP-1409452-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2004-04-21 EP disclosed
WO-2002098846-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147612-A1 Sulfonamide derivatives GRIN1, GRIN2A, GRIA1 GRIA4 9/4885CA12 1432/4885CA1 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.